[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"notifications-list":3,"$f1f7vzkj0sjhwf":5},{"data":4},[],{"data":6,"error":10},{"id":7,"documentId":8,"slug":9,"name":9,"proprietary_name":10,"non_proprietary_name":10,"is_proprietary":10,"active_ingredient":10,"administration_route":10,"available_strength":10,"dosage_form":10,"dose_schedule":10,"drug_unit":10,"is_available_generically":10,"mechanism_of_action":10,"overdosage":10,"warning":10,"species":11,"citations":12,"dose_schedules":27,"available_strengths":40,"label_statements":45,"drug_classes":65,"specialties":71,"medical_conditions":72,"animal_species":73},1880,"zeyamwa4oyp0zw46hsuy362v","toceranib",null,[],[13,19,23],{"source":14,"licence":15,"source_url":16,"harvested_by":17,"retrieved_at":18},"EMA centrally authorised medicines","EMA reuse with attribution","https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fdocuments\u002Freport\u002Fmedicines-output-medicines-report_en.xlsx","load-reference-corpus.cjs","2026-09-07",{"source":20,"licence":21,"source_url":22,"harvested_by":17,"retrieved_at":18},"FDA Green Book","US public domain","https:\u002F\u002Fanimaldrugsatfda.fda.gov\u002Fadafda\u002Fapp\u002Fsearch\u002Fpublic\u002FingredientsInformationExcel\u002FSection2ActiveIngredients",{"source":24,"licence":25,"source_url":26,"harvested_by":17,"retrieved_at":18},"UK VMD PID","OGL v3.0","https:\u002F\u002Fwww.vmd.defra.gov.uk\u002Fproductinformationdatabase\u002Fdownloads\u002Fvmd_productinformationdatabase.xlsx",[28,35],{"id":29,"dose_text":30,"species":31,"administration_route":32,"limitation":33,"source_label":34},13859,"Administer an initial dosage of 3.25 mg\u002Fkg (1.48 mg\u002Flb) body weight, orally every other day.","Dogs","Oral","For oral use in dogs only.\nDo not use in dogs used for breeding, or for pregnant or lactating bitches.\nDo not split tablets.\nFederal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.","Palladia®",{"id":36,"dose_text":37,"species":10,"administration_route":38,"limitation":10,"source_label":39},13860,"Always provide Client Information Sheet with prescription. Administer an initial dosage of 3.25 mg\u002Fkg (1.48 mg\u002Flb) body weight, orally every other day (see Table 1). Dose reductions of 0.5 mg\u002Fkg (to a minimum dose of 2.2 mg\u002Fkg (1.0 mg\u002Flb) every other day) and dose interruptions (cessation of PALLADIA for up to two weeks) may be utilized, if needed, to manage adverse reactions (see Table 2 as well as\nWarnings\nand\nPrecautions\n). Adjust dose based on approximately weekly veterinary assessments for the first 6 weeks and approximately every 6 weeks, thereafter. PALLADIA may be administered with or without food. Do not split tablets.\nTable 1. 3.25 mg\u002Fkg Dose Chart\nDog Body Weight\nNumber of Tablets\nPounds\nKilograms\nDose\n10 mg\n15 mg\n50 mg\n11.0 – 11.8\n5.0 - 5.3\n15 mg\n1\n11.9 – 15.2\n5.4 - 6.9\n20 mg\n2\n15.3 – 18.5\n7.0 - 8.4\n25 mg\n1\n1\n18.6 – 22.0\n8.5 - 10.0\n30 mg\n2\n22.1 – 25.4\n10.1 - 11.5\n35 mg\n2\n1\n25.5 – 28.7\n11.6 - 13.0\n40 mg\n1\n2\n28.8 – 32.2\n13.1 - 14.6\n45 mg\n3\n32.3 – 35.5\n14.7 - 16.1\n50 mg\n1\n35.6 – 38.8\n16.2 - 17.6\n55 mg\n1\n3\n38.9 – 42.3\n17.7 - 19.2\n60 mg\n1\n1\n42.4 – 45.6\n19.3 - 20.7\n65 mg\n1\n1\n45.7 – 50.7\n20.8 - 23.0\n70 mg\n2\n1\n50.8 – 59.3\n23.1 - 26.9\n80 mg\n2\n1\n59.4 – 65.9\n27.0 - 29.9\n95 mg\n3\n1\n66.0 – 71.2\n30.0 - 32.3\n100 mg\n2\n71.3 – 76.3\n32.4 - 34.6\n110 mg\n1\n2\n76.4 – 79.6\n34.7 - 36.1\n115 mg\n1\n2\n79.7 – 84.7\n36.2 - 38.4\n120 mg\n2\n2\n84.8 – 94.8\n38.5 - 43.0\n130 mg\n2\n2\n94.9 – 105.0\n43.1 - 47.6\n150 mg\n3\n105.1 – 110.0\n47.7 - 49.9\n160 mg\n1\n3\n110.1 – 113.5\n50.0 - 51.5\n165 mg\n1\n3\n113.6 – 118.6\n51.6 - 53.8\n170 mg\n2\n3\n118.7 – 128.8\n53.9 - 58.4\n180 mg\n2\n3\n128.9 – 138.9\n58.5 - 63.0\n200 mg\n4\n139.0 – 144.0\n63.1 - 65.3\n210 mg\n1\n4\n144.1 – 157.6\n65.4 - 71.5\n215 mg\n1\n4\n157.7 – 173.1\n71.6 - 78.5\n250 mg\n5\n173.2 – 177.9\n78.6 - 80.7\n260 mg\n1\n5\n178.0 – 191.6\n80.8 - 86.9\n265 mg\n1\n5\n191.7 – 220.5\n87.0 - 100.0\n300 mg\n6\nTable 2. Dose Modification Based on Toxicity Observed\nToxicity\nDose Adjustment\nNeutropenia\n>1000\u002FµL\nMaintain dose level\n≤1000\u002FµL or neutropenic fever or infection\nStop drug until >1000\u002FµL and clinical signs normal; then decrease dose by 0.5 mg\u002Fkg\nRenal Toxicities (Creatinine)\n\u003C2.0 mg\u002FdL\nMaintain dose level\n≥2.0 mg\u002FdL\nStop drug until \u003C2.0 mg\u002FdL then decrease dose by 0.5 mg\u002Fkg\nAlbumin\n\u003C1.5 g\u002FdL\nStop drug until >2.5 g\u002FdL then decrease dose by 0.5 mg\u002Fkg\nHematocrit\n\u003C26%\nStop drug until >30% then decrease dose by 0.5 mg\u002Fkg\nDiarrhea\n\u003C4 watery stools\u002Fday for less than 2 days\nMaintain dose level and institute supportive care\n≥4 watery stools\u002Fday or ≥ 2 days\nStop drug until formed stools and institute supportive care. When dosing is resumed, decrease dose by 0.5 mg\u002Fkg\nGI Bleeding\nFresh blood in stool or black tarry stool for > 2 days or frank hemorrhage or blood clots in stool.\nStop drug and institute supportive care until resolution of all clinical signs of blood in stool, then decrease dose by 0.5 mg\u002Fkg.","ORAL","Palladia® 10 mg 15 mg 50 mg (toceranib phosphate) Tablets",[41],{"id":42,"strength_text":43,"dosage_form":44,"proprietary_name":34,"species":31,"source_label":34},12038,"Each tablet contains 10, 15, or 50 mg toceranib as toceranib phosphate.","Tablet",[46,50,53,57,61],{"id":47,"kind":48,"statement":49,"species":31,"limitation":33,"source_label":34},20397,"indication","For the treatment of Patnaik grade II or III, recurrent, cutaneous mast cell tumors with or without regional lymph node involvement in dogs.",{"id":51,"kind":48,"statement":52,"species":10,"limitation":10,"source_label":39},20398,"PALLADIA tablets are indicated for the treatment of Patnaik grade II or III, recurrent, cutaneous mast cell tumors with or without regional lymph node involvement in dogs.",{"id":54,"kind":55,"statement":56,"species":10,"limitation":10,"source_label":39},20399,"contraindication","Do not use in dogs used for breeding, or for pregnant or lactating bitches (see Clinical Pharmacology).",{"id":58,"kind":59,"statement":60,"species":10,"limitation":10,"source_label":39},20400,"warning","PALLADIA may cause vascular dysfunction which can lead to edema and thromboembolism, including pulmonary thromboembolism. Discontinue drug until clinical signs and clinical pathology have normalized. To assure vasculature homeostasis, wait at least 3 days after stopping drug before performing surgery (see\nAdverse Reactions\n).\nSerious and sometimes fatal gastrointestinal complications including gastrointestinal perforation have occurred rarely in dogs treated with PALLADIA (see\nAdverse Reactions\n). If gastrointestinal ulceration is suspected, stop drug administration and treat appropriately.",{"id":62,"kind":63,"statement":64,"species":10,"limitation":10,"source_label":39},20401,"adverse_reaction","A US clinical field study comprised of a 6-week masked phase, followed by an open-label phase, evaluated the safety and effectiveness of PALLADIA in 151 client-owned dogs that had Patnaik grade II or III, recurrent, cutaneous mast cell tumors with or without regional lymph node involvement. The most common adverse reactions reported during the masked phase are summarized in Table 3; those reported during the entire study (masked phase combined with the open-label phase) are summarized in Table 4.\nTable 3. Summary of the most common adverse reactions during the masked phaseThe mean time on study during the masked phase was 37.0 days for PALLADIA-treated dogs (median, 42.0 days) and 27.6 days for placebo-treated dogs (median, 21.0 days); no adjustments were made in the statistical comparisons for this disparity.\nPlacebo (n = 64)\nPALLADIA (n = 87)\nAdverse Reaction\nAny GradeInvestigators assigned severity grade of 1, 2, 3 or 4 (1 - least severe; 4 - most severe).\nGrade 3 or 4\nAny Grade\nGrade 3 or 4\nDiarrhea\n26.6%\n3.1%\n46.0%\n6.9%\nAnorexia\n31.3%\n6.3%\n39.1%\n6.9%\nLethargy\n29.7%\n3.1%\n35.6%\n4.6%\nVomiting\n32.8%\n6.3%\n32.2%\n9.2%\nLameness\n9.4%\n0.0%\n17.2%\n0.0%\nWeight loss\n3.1%\n0.0%\n14.9%\n1.1%\nBlood in stool\u002FGI bleed\u002Fhemorrhagic diarrhea\n3.1%\n0.0%\n12.6%\n2.3%\nMusculoskeletal disorder\n6.3%\n0.0%\n11.5%\n1.1%\nDehydration\n4.7%\n0.0%\n9.2%\n2.3%\nDermatitis\n9.4%\n1.6%\n9.2%\n0.0%\nPruritus\n4.7%\n0.0%\n9.2%\n0.0%\nTachypnea\n4.7%\n0.0%\n8.0%\n1.1%\nLocalized pain\n4.7%\n0.0%\n8.0%\n0.0%\nNausea\n3.1%\n0.0%\n8.0%\n1.1%\nGeneral pain\n4.7%\n1.6%\n6.9%\n0.0%\nPolydipsia\n7.8%\n0.0%\n6.9%\n0.0%\nPyrexia\n3.1%\n0.0%\n5.7%\n2.3%\nFlatulence\n3.1%\n0.0%\n5.7%\n0.0%\nPigmentation disorder\n1.6%\n0.0%\n5.7%\n0.0%\nLaboratory Abnormality\nAny GradeGrading of laboratory abnormalities was based on the National Cancer Institute's Common Toxicity Criteria guideline adapted for canines (1 - least severe; 4 - most severe).\nGrade 3 or 4\nAny Grade\nGrade 3 or 4\nNeutropenia\n6.3%\n0.0%\n46.0%\n0.0%\nThrombocytopenia\n20.3%\n0.0%\n24.1%\n0.0%\nIncreased alanine aminotransferase\n21.9%\n4.7%\n24.1%\n1.1%\nHypoalbuminemia\n7.8%\n0.0%\n12.6%\n0.0%\nDecreased hematocrit\n7.8%\n0.0%\n5.7%\n3.4%\nHyperbilirubinemia\n1.6%\n1.6%\n5.7%\n0.0%\nIncreased creatinine\n4.7%\n0.0%\n5.7%\n0.0%\nUrinary tract infection\n1.6%\n0.0%\n5.7%\n0.0%\nTable 4. Summary of the most common adverse reactions during the study (masked phase combined with the open-label phase)The duration of treatment with PALLADIA ranged from 2 to 812 days (mean, 144 days; median, 68 days). All dogs received at least 1 dose of PALLADIA.\nPALLADIA (n = 145)\nOther adverse events were reported but occurred in \u003C 5% of dogs. Any individual dog may have had multiple adverse events.\nAdverse Reactions\nAny GradeInvestigators assigned severity grade of 1, 2, 3 or 4 (1 – least severe; 4 – most severe).\nGrade 3 or 4\nDiarrhea\n58.6%\n8.3%\nAnorexia\n49.7%\n8.3%\nVomiting\n47.6%\n9.7%\nLethargy\n39.3%\n4.1%\nLameness\n22.8%\n0.0%\nWeight loss\n21.4%\n2.8%\nBlood in stool\u002FGI bleed\u002Fhemorrhagic diarrhea\n18.6%\n2.8%\nDehydration\n15.2%\n2.1%\nPruritus\n12.4%\n0.0%\nPigmentation disorder\n11.7%\n0.0%\nDermatitis\n11.0%\n0.0%\nMusculoskeletal disorder\n11.0%\n0.0%\nGeneral pain\n8.3%\n0.0%\nOtitis externa\n8.3%\n0.0%\nTachypnea\n8.3%\n0.0%\nNausea\n7.6%\n1.4%\nPolydipsia\n7.6%\n0.0%\nPyrexia\n6.9%\n2.8%\nArthritis\n6.2%\n0.0%\nLocalized edema\n6.2%\n0.0%\nBacterial skin infection\n5.5%\n0.0%\nConjunctivitis\n5.5%\n0.0%\nLaboratory Abnormality\nAny GradeGrading of laboratory abnormalities was based on the National Cancer Institute's Common Toxicity Criteria guideline adapted for canines (1 – least severe; 4 – most severe).\nGrade 3 or 4\nNeutropenia\n44.8%\n1.4%\nHypoalbuminemia\n28.3%\n1.4%\nThrombocytopenia\n28.3%\n2.1%\nIncreased alanine aminotransferase\n27.6%\n4.1%\nDecreased hematocrit\n11.0%\n2.8%\nIncreased creatinine\n13.8%\n1.4%\nHyperbilirubinemia\n6.9%\n0.0%\nUrinary tract infection\n7.6%\n0.0%\nThere were 5 deaths during this study that were possibly drug related. Pathology findings generally revealed evidence of vascular dysfunction including pulmonary thromboembolism (post-operative); multi-organ failure associated with vasculitis and thrombosis; vascular thrombosis with disseminated intravascular coagulopathy (DIC) and pancreatitis; and vasculitis with DIC. One dog died secondary to gastric perforation; the duration of treatment with PALLADIA was 221 days and there was no evidence of mast cell tumor at necropsy. These deaths occurred in the presence or absence of gross-disease; treatment durations ranged from 18 to 221 days.\nThe relationship of the following deaths to drug are unknown. One dog, first treated for 3 weeks with a placebo, died of unknown cause 7 days after initiation of PALLADIA therapy. Another dog died of unknown cause 92 days after initiation of PALLADIA therapy. No necropsy was conducted in either dog.\nTwenty seven dogs developed some form of gastrointestinal bleeding with 2.8% of dogs having severe bleeding. One dog developed gastric ulceration which was possibly drug related. Three dogs died from gastric (1 dog) or duodenal (2 dogs) perforations during the study. One dog with a duodenal perforation received only 1 dose of study drug and, therefore, was not considered drug related.\nSeven dogs developed nasal depigmentation within the first few weeks of treatment. Eleven dogs developed coat color or skin changes during the study. Two of these dogs had complete coat color changes from fawn to white and from deep red to blonde. Seven dogs experienced alopecia.\nThere is a drug related effect on body weight: 20.0% of dogs had >13% weight loss in the masked plus open-label phase attributable to drug. Of these, 5 dogs had >25% weight loss. Three dogs had seizure-like activity while on study drug. It can not be determined if these were drug related.\nTwo dogs developed epistaxis that was not associated with thrombocytopenia. Another dog developed epistaxis with concurrent disseminated intravascular coagulopathy.\nFor a copy of the Material Safety Data Sheet (MSDS) or to report adverse events call Zoetis at 1-888-963-8471.",[66],{"id":67,"documentId":68,"slug":69,"name":70},976,"gcy2dfr7bv8mt5dc5u5pauiy","antineoplastic-agents","Antineoplastic agents",[],[],[]]